ICON Announces the Expansion of its Accellacare Site Network
Published on:
ICON plc, a global provider of drug development and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations, today announced that its Accellacare Site Network has expanded in reach and capabilities through new partnerships with six research sites across four countries.
Agreements with Asclepes Research and Olympian Clinical Research in the US, Curiositas ad Sanum and Intermed in Germany, Quironsalud in Spain, and KO-MED in Poland brings the Accellacare network to 112 active locations across eight countries and the entry to two new US states–Florida and California. Through these new partnerships, Accellacare is also enhancing its capability in the central nervous system (CNS) and immune-inflammation therapeutic areas.
